CN106232182B - S1p3拮抗剂 - Google Patents

S1p3拮抗剂 Download PDF

Info

Publication number
CN106232182B
CN106232182B CN201480074769.6A CN201480074769A CN106232182B CN 106232182 B CN106232182 B CN 106232182B CN 201480074769 A CN201480074769 A CN 201480074769A CN 106232182 B CN106232182 B CN 106232182B
Authority
CN
China
Prior art keywords
bromo
pyridin
amide
pentanoic acid
pyrazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480074769.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106232182A (zh
Inventor
奇亚拉·卡拉梅丽
切萨雷·费德里科
埃马努埃莱·加白里艾瑞
马泰奥·马尼亚尼
约兰达·米科
格奥尔格·C·泰斯塔潘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN106232182A publication Critical patent/CN106232182A/zh
Application granted granted Critical
Publication of CN106232182B publication Critical patent/CN106232182B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16—Halogen atoms; Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201480074769.6A 2013-12-02 2014-11-28 S1p3拮抗剂 Active CN106232182B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195372.1A EP2878339A1 (en) 2013-12-02 2013-12-02 SIP3 antagonists
EP13195372.1 2013-12-02
PCT/EP2014/075986 WO2015082357A1 (en) 2013-12-02 2014-11-28 S1p3 antagonists

Publications (2)

Publication Number Publication Date
CN106232182A CN106232182A (zh) 2016-12-14
CN106232182B true CN106232182B (zh) 2019-11-01

Family

ID=49674243

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480074769.6A Active CN106232182B (zh) 2013-12-02 2014-11-28 S1p3拮抗剂

Country Status (12)

Country Link
US (4) US9951017B2 (enExample)
EP (4) EP2878339A1 (enExample)
JP (2) JP6595475B2 (enExample)
KR (1) KR102386815B1 (enExample)
CN (1) CN106232182B (enExample)
AU (1) AU2014359489B2 (enExample)
CA (1) CA2932218C (enExample)
EA (1) EA034218B1 (enExample)
NZ (1) NZ721802A (enExample)
UA (1) UA117154C2 (enExample)
WO (1) WO2015082357A1 (enExample)
ZA (1) ZA201604490B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
KR102131677B1 (ko) 2018-03-20 2020-08-05 주식회사 아하 가이드 모듈 및 하폐수 처리용 산기장치
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito
KR102335637B1 (ko) * 2020-03-13 2021-12-06 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
CN116568671A (zh) * 2020-10-16 2023-08-08 分子医学研究中心责任有限公司 杂环Cullin-RING泛素连接酶化合物及其用途
WO2023275796A1 (en) * 2021-07-01 2023-01-05 Novartis Ag Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors
JP2025526266A (ja) * 2022-07-05 2025-08-13 オーリジーン オンコロジー リミテッド Ｃｄｋ１２／１３阻害剤としての置換ｎ－（ピリジン－２－イル）アセトアミド誘導体

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020313A1 (en) * 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
WO2005058295A2 (en) * 2003-12-19 2005-06-30 Novartis Ag Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
CN1658871A (zh) * 2001-12-21 2005-08-24 诺沃挪第克公司 作为gk活化剂的酰胺衍生物
WO2008141013A1 (en) * 2007-05-08 2008-11-20 Allergan, Inc. S1p3 receptor inhibitors for treating pain
WO2011008475A1 (en) * 2009-06-30 2011-01-20 Allergan, Inc. Optionally substituted 2-(arylmethyl, aryloxy or arylthio) -n- pyridin-2 -yl-aryl acetamide or 2, 2-bis (aryl) -n-pyridin-2-yl acetamide compounds as medicaments for the treatment of eye diseases
WO2011019681A1 (en) * 2009-08-11 2011-02-17 Allergan, Inc. Selective sphingosine-1-phosphate receptor antagonists
CN103119038A (zh) * 2010-04-23 2013-05-22 百时美施贵宝公司 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1,2,4-噁二唑基-3-基)扁桃酰胺
WO2013158939A1 (en) * 2012-04-18 2013-10-24 Hemoshear, Llc In vitro model for pathological or physiologic conditions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081756B1 (en) 1981-12-14 1985-05-15 MEDEA RESEARCH S.r.l. New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
WO1998015278A1 (en) 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
CN1384832A (zh) 1999-11-18 2002-12-11 诺瓦提斯公司 作为农药的氨基杂环基酰胺化合物
ES2233660T3 (es) 2000-05-03 2005-06-16 F. Hoffmann-La Roche Ag Activadores de glucokinasa alquinil fenil heteroaromaticos.
JP4742333B2 (ja) 2000-11-13 2011-08-10 日本農薬株式会社 Ｎ−チアジアゾリルシクロプロパンカルボン酸アミド類およびこれを有効成分とする殺虫、殺ダニ剤
DK1341774T3 (da) 2000-12-06 2006-06-12 Hoffmann La Roche Kondenserede heteroaromatiske glucokinase-aktivatorer
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
EA011297B1 (ru) 2002-04-26 2009-02-27 Ф. Хоффманн-Ля Рош Аг Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
EP1594863A1 (en) * 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL1700856T3 (pl) * 2003-12-26 2016-05-31 Kyowa Hakko Kirin Co Ltd Pochodna tiazolu
WO2005075435A1 (en) 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
JP2008521864A (ja) 2004-12-03 2008-06-26 トランステック・ファーマ、インコーポレイテッド ヘテロ芳香族グルコキナーゼ活性化剤
US7888374B2 (en) * 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
CA2621227A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
EP1935874A4 (en) * 2005-10-12 2010-10-13 Toa Eiyo Ltd S1P3 RECEPTOR ANTAGONIST
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
NZ569327A (en) 2005-12-28 2011-09-30 Vertex Pharma 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
WO2008063625A2 (en) * 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008119734A2 (en) 2007-03-29 2008-10-09 Novartis Ag Process for the manufacture of organic compounds
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CA2687764A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
KR20100113518A (ko) 2008-01-18 2010-10-21 아스텔라스세이야쿠 가부시키가이샤 페닐아세트아미드 유도체
CA2716515A1 (en) * 2008-02-21 2009-08-27 Boehringer Ingelheim International Gmbh Amine and ether compounds which modulate the cb2 receptor
PT2615085E (pt) 2008-03-31 2015-10-09 Vertex Pharma Derivados piridilo como moduladores cftr
WO2009140624A2 (en) * 2008-05-16 2009-11-19 Takeda San Diego, Inc. Glucokinase activators
EA201100311A1 (ru) 2008-09-11 2011-10-31 Пфайзер Инк. Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
WO2012082817A1 (en) * 2010-12-16 2012-06-21 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020313A1 (en) * 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
CN1658871A (zh) * 2001-12-21 2005-08-24 诺沃挪第克公司 作为gk活化剂的酰胺衍生物
WO2005058295A2 (en) * 2003-12-19 2005-06-30 Novartis Ag Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
WO2008141013A1 (en) * 2007-05-08 2008-11-20 Allergan, Inc. S1p3 receptor inhibitors for treating pain
WO2011008475A1 (en) * 2009-06-30 2011-01-20 Allergan, Inc. Optionally substituted 2-(arylmethyl, aryloxy or arylthio) -n- pyridin-2 -yl-aryl acetamide or 2, 2-bis (aryl) -n-pyridin-2-yl acetamide compounds as medicaments for the treatment of eye diseases
WO2011019681A1 (en) * 2009-08-11 2011-02-17 Allergan, Inc. Selective sphingosine-1-phosphate receptor antagonists
CN103119038A (zh) * 2010-04-23 2013-05-22 百时美施贵宝公司 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1,2,4-噁二唑基-3-基)扁桃酰胺
WO2013158939A1 (en) * 2012-04-18 2013-10-24 Hemoshear, Llc In vitro model for pathological or physiologic conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Discovery, design and synthesis of a selective S1P agonist;Miguel Guerrero等;《Bioorg. Med. Chem. Lett.》;20131001;第23卷(第23期);第6346-6349页 *
Regiospecific loss of essential lipids sphingosine 1-phosphate and galactosylceramide early in Alzheimer"s disease pathogenesis;AnthonyDon等;《Alzheimer"s & Dementia》;20131009;第9卷(第4期);第712-713页 *
S1P信号通路及其在神经系统疾病中的作用;孙翠梅等;《山东省2013年神经内科学学术会议暨中国神经免疫大会2013论文汇编》;20130907;第264页 *

Also Published As

Publication number Publication date
EA034218B1 (ru) 2020-01-17
EP3086845B1 (en) 2019-11-20
WO2015082357A1 (en) 2015-06-11
EP3896068A1 (en) 2021-10-20
US20220402875A1 (en) 2022-12-22
JP6595475B2 (ja) 2019-10-23
EP2878339A1 (en) 2015-06-03
US11472772B2 (en) 2022-10-18
HK1226017A1 (en) 2017-09-22
US9951017B2 (en) 2018-04-24
EP3689864A1 (en) 2020-08-05
CA2932218A1 (en) 2015-06-11
EP3086845A1 (en) 2016-11-02
US20200157052A1 (en) 2020-05-21
CA2932218C (en) 2023-10-03
JP2016539174A (ja) 2016-12-15
UA117154C2 (uk) 2018-06-25
AU2014359489B2 (en) 2020-01-30
US20180201582A1 (en) 2018-07-19
US20160297762A1 (en) 2016-10-13
NZ721802A (en) 2022-04-29
AU2014359489A1 (en) 2016-07-21
KR20160093710A (ko) 2016-08-08
EA201691160A1 (ru) 2016-11-30
CN106232182A (zh) 2016-12-14
KR102386815B1 (ko) 2022-04-14
ZA201604490B (en) 2019-11-27
JP2020023512A (ja) 2020-02-13

Similar Documents

Publication Publication Date Title
CN106232182B (zh) S1p3拮抗剂
TWI433830B (zh) 胺基羧酸衍生物及其醫藥用途
JP6990110B2 (ja) タンパク質症を処置するための方法
TW200911254A (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842
JPWO2006001463A1 (ja) Ｓ１ｐ受容体結合能を有する化合物およびその用途
JP2021514963A (ja) ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体
JP2008503490A (ja) チロシンホスファターゼの三置換窒素調節物質
TW201206912A (en) Pharmaceutical combination
JP2022519131A (ja) グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置
CN102271679A (zh) 包含磺酰胺的化合物及其用途
EP1613326A1 (en) (3-{3-´(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino!-propoxy}-phenyl)-acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders
JPWO2004080943A1 (ja) シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
JP2007523087A (ja) Ｌｘｒモジュレーターとしての化合物および組成物
US6924295B2 (en) Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
CN108239073A (zh) 化合物、医药组成物及其用途
HK1227786A1 (zh) S1p3拮抗剂
HK1227786B (zh) S1p3拮抗剂
HK1226017B (en) S1p3 antagonists
WO2014114649A1 (en) Lipase inhibitors
WO2025153719A1 (en) Pla2g15 inhibitors
FR2894964A1 (fr) Composes a base de quatre cycles aromatiques, preparation et utilisations
CN119300826A (zh) 包含氮杂螺庚烷核的t型钙通道调节剂和其使用方法
MXPA06009159A (en) Compounds and compositions as lxr modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1227786

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant